Remission, Molecular Remission, and Cure in Psoriatic Disease

Conclusions

• The presentation concludes that psoriasis care is moving beyond skin clearance alone toward remission, molecular remission, and potentially cure as the next therapeutic goals.
• It argues that on-treatment remission is now a measurable and clinically meaningful endpoint defined by complete skin clearance sustained on therapy for a defined period.
• Patient-reported data suggest many people consider themselves in remission even without total clearance, and remission is associated with better quality of life.
• The speaker concludes that remission cannot be defined by body surface area alone and should eventually incorporate patient-reported outcomes and other multidimensional measures.
• Newer biologic therapies can help substantial proportions of patients achieve and maintain stringent on-treatment remission over long periods.
• The work suggests that remission definitions in psoriasis are influencing related fields such as atopic dermatitis and psoriatic arthritis.
• The presentation concludes that psoriatic arthritis remission remains a work in progress, but consensus efforts are underway to define it using clinical, symptom, and imaging domains.
• Although cure is not yet a practical clinical reality, the literature suggests it may eventually become conceivable through early intervention, combination treatment, prevention, or other mechanistic advances.
• Overall, the presentation concludes that remission is no longer just a concept but an endpoint that is increasingly relevant for trials, patients, and future regulatory frameworks.